查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540816

2024-2032 年按产品与服务、技术（免疫组织化学、聚合酶连锁反应、原位杂交、即时 PCR、基因定序等）、适应症、最终用户和地区分類的伴随诊断市场报告

Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球伴随诊断市场规模达到 67 亿美元。癌症发生率的上升、对个人化医疗的需求不断增加以及包括下一代定序（NGS）在内的持续技术进步是推动伴随诊断市场成长的一些主要因素。

全球伴随诊断市场分析：

主要市场驱动因素：对更有针对性和更有效的癌症治疗的日益增长的需求正在积极影响伴随诊断的市场前景。此外，针对患者每个独特特征的个人化药物的日益使用也刺激了伴随诊断市场的需求。

主要市场趋势：推动伴随诊断市场价值的新兴趋势之一是对治疗各种神经、心血管和发炎性疾病的标靶疗法和药物的需求不断增长。除此之外，诊断技术的不断进步，例如下一代定序（NGS）的发展，是刺激伴随诊断市场收入的成长因素。

地理趋势：根据伴随诊断市场研究，北美目前主导全球市场。越来越多的测试获得包括美国食品和药物管理局 (US FDA) 在内的管理机构的批准，正在扩大区域市场。此外，他们也专注于临床试验，从而刺激北美伴随诊断市场的收入。

竞争格局：根据伴随诊断市场概述，全球市场上的一些知名公司包括雅培实验室、安捷伦科技、生物梅里埃、丹纳赫公司、罗氏控股公司、Myriad Genetics Inc.、西门子医疗保健和赛默飞世尔科技公司。

挑战与机会：阻碍​​伴随诊断市场预测的主要挑战之一是临床试验期间广泛的药物损耗率，这反过来又给诊断提供者带来了财务限制。然而，伴随诊断与治疗产品的共同开发正在简化候选药物的商业化。

全球伴随诊断市场趋势：

对标靶治疗的需求不断增长

在肺癌标靶治疗相关治疗决策中越来越多地采用伴随诊断测试（CDX）正在促进市场成长。此外，在初始治疗中接受伴随诊断的患者比未接受检测的患者有更多的生存益处。除此之外，非小细胞肺癌（NSCLC）盛行率的不断增加导致该疾病的肿瘤学伴随诊断测试的使用量增加。据肺癌研究基金会称，2022 年全美估计有 236,740 人被诊断出患有肺癌，从而刺激了对肺癌伴随诊断的需求。获得管理当局批准的测试数量不断增加也提振了市场。例如，2022 年 8 月，美国 FDA 批准 Thermo Fisher Scientific 的 Oncomine Dx 标靶测试作为伴随诊断 (CDx)，以识别肿瘤中存在 HER2 (ERBB2) 激活突变（SNV 和外显子 20 插入）的个体。小细胞肺癌（NSCLC）。

伴随诊断的有利监管环境

各国政府机构和主要公司都在关注药物审批，以满足未满足的癌症治疗需求。例如，2022年1月，PREMIA控股（香港）有限公司和淘大诊断有限公司在日本开发了AmoyDx泛肺癌PCR检测试剂盒（「PLC检测试剂盒」），作为多种抗癌药物的报销伴随诊断。同样，2021 年 10 月，美国食品和药物管理局批准了安捷伦的 Ki-67 IHC MIB-1 pharmDx (Dako Omnis)，该产品有助于识别疾病復发风险较高的早期乳癌 (EBC) 患者。此外，2023 年 8 月，安捷伦科技公司获得了伴随诊断检测的欧洲 IVDR 认证。这些批准鼓励主要参与者开发增强型伴随诊断测试，预计在预测期内扩大全球市场。

新颖测试的开发

主要参与者正致力于透过与其他知名参与者合作推出先进的伴随诊断测试，从而获得更好的患者治疗结果。例如，2022年2月，中国主要从事早期癌症筛检产品、分子谱测试和伴随诊断开发的精准肿瘤平台公司泛生子控股有限公司与HTCHMED（中国）有限公司达成协议，推出伴随诊断产品（CDx） 。此外，主要市场参与者也在开发增强的治疗选择。例如，Labcorp 于 2021 年 7 月推出了 Therascreen KRAS PCR 突变分析，这是一种伴随诊断，用于识别患有非小细胞肺癌 (NSCLC) 的患者是否有资格接受 LUMAKRAS (sotorasib) 治疗。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球伴随诊断市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品与服务

  • 测定、试剂盒和试剂
    • 市场趋势
    • 市场预测
  • 软体和服务
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依技术

  • 免疫组织化学 (IHC)
    • 市场趋势
    • 市场预测
  • 聚合酶炼式反应 (PCR)
    • 市场趋势
    • 市场预测
  • 原位杂交 (ISH)
    • 市场趋势
    • 市场预测
  • 即时萤光定量PCR (RT-PCR)
    • 市场趋势
    • 市场预测
  • 基因定序
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依迹象

  • 癌症
    • 市场趋势
    • 主要类型
      • 肺癌
      • 乳癌
      • 大肠直肠癌
      • 胃癌
      • 黑色素瘤
      • 其他的
    • 市场预测
  • 神经系统疾病
    • 市场趋势
    • 市场预测
  • 传染病
    • 市场趋势
    • 市场预测
  • 心血管疾病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 製药及生物製药公司
    • 市场趋势
    • 市场预测
  • 参考实验室
    • 市场趋势
    • 市场预测
  • 合约研究组织
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Agilent Technologies
    • BioMerieux
    • Danaher Corporation
    • Roche Holding AG
    • Myriad Genetics Inc.
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc.
Product Code: SR112024A2548

The global companion diagnostics market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.4 Billion by 2032, exhibiting a growth rate (CAGR) of 12.7% during 2024-2032. The rising incidences of cancer, the increasing demand for personalized medicine, and continuous technological advancements, including next-generation sequencing (NGS), are some of the primary factors driving the companion diagnostics market growth.

Global Companion Diagnostics Market Analysis:

Major Market Drivers: The growing need for more targeted and effective cancer treatments is positively influencing the companion diagnostics market outlook. Additionally, the increasing usage of personalized medicines tailored to each unique characteristics of patients is also stimulating the companion diagnostics market demand.

Key Market Trends: One of the emerging trends propelling the companion diagnostics market value is the inflating demand for targeted therapies and drugs to treat various neurological, cardiovascular, and inflammatory conditions. Besides this, continuous advancements in diagnostic technologies, such as the development of next-generation sequencing (NGS), represent growth factors stimulating the companion diagnostics market revenue.

Geographical Trends: According to the companion diagnostics market research, North America currently dominates the global market. The increasing number of tests receiving approval from governing authorities, including the United States Food and Drug Administration (US FDA), is augmenting the regional market. Furthermore, they are also focusing on clinical trials, thereby stimulating the companion diagnostics market revenue in North America.

Competitive Landscape: According to the companion diagnostics market overview, some of the prominent companies in the global market include Abbott Laboratories, Agilent Technologies, BioMerieux, Danaher Corporation, Roche Holding AG, Myriad Genetics Inc., Siemens Healthcare, and Thermo Fisher Scientific Inc., among many others.

Challenges and Opportunities: One of the primary challenges hindering the companion diagnostics market forecast is the extensive drug attrition rate during clinical trials, which, in turn, poses financial constraints for diagnostics providers. However, the co-development of companion diagnostics, along with therapeutic products, is streamlining the commercialization of drug candidates.

Global Companion Diagnostics Market Trends:

Rising Need for Targeted Therapies

The increasing adoption of companion diagnostic tests (CDXs) in decision-making for treatment related to targeted therapies in lung cancer is augmenting the market growth. Additionally, patients who receive companion diagnostics as part of their initial treatment have more survival benefits than those who are not tested. Besides this, the increasing prevalence of non-small cell lung cancer (NSCLC) is inflating the usage of oncology companion diagnostic tests for the disease. According to the Lung Cancer Research Foundation, an estimated 236,740 individuals were diagnosed with lung cancer in 2022 across the United States, thereby fueling the demand for lung cancer companion diagnostics. The elevating number of tests receiving approval from governing authorities is also bolstering the market. For example, in August 2022, the U.S. FDA granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to identify individuals whose tumors have a HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion) in non-small cell lung cancer (NSCLC).

Favorable Regulatory Landscape for Companion Diagnostics

Government bodies and key companies across the countries are focusing on drug approvals to cater to unmet cancer care needs. For instance, in January 2022, PREMIA Holdings (HK) Limited and Amoy Diagnostics Co. Ltd developed the AmoyDx Pan Lung Cancer PCR Panel (the 'PLC Panel') in Japan as a reimbursed companion diagnostic for numerous anti-cancer agents. Similarly, in October 2021, the United States Food and Drug Administration approved Agilent's Ki-67 IHC MIB-1 pharmDx (Dako Omnis), which helped in identifying patients with early breast cancer (EBC) at an elevating risk of disease recurrence. In addition, in August 2023, Agilent Technologies, Inc. received European IVDR certification for companion diagnostic assay. These approvals encourage key players to develop enhanced companion diagnostic tests, which are expected to augment the global market over the forecasted period.

Development of Novel Tests

Key players are focusing on launching advanced tests for companion diagnostics by collaborating with other prominent players, thereby resulting in better patient outcomes. For instance, in February 2022, Genetron Holdings Limited, a major precision oncology platform company in China specializing in early cancer screening products, molecular profiling tests, and companion diagnostics development, entered into an agreement with HUTCHMED (China) Limited to introduce a companion diagnostic (CDx). Furthermore, key market players are also developing enhanced therapeutic options. For example, in July 2021, Labcorp launched Therascreen KRAS PCR Mutation Analysis, which is a companion diagnostic to identify patients suffering from non-small cell lung cancer (NSCLC) who are eligible for therapy with LUMAKRAS (sotorasib).

Companion Diagnostics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product & service, technology, indication, and end user.

Breakup by Product & Service:

Assays, Kits and Reagents

Software and Services

Assays, kits and reagents hold the largest market share

The report has provided a detailed breakup and analysis of the companion diagnostics market based on the product & service. This includes assays, kits and reagents, and software and services. According to the report, assays, kits, and reagents represented the largest segment.

Assays, kits, and reagents play important roles in identifying patients who are most likely to benefit from a particular therapeutic product. These diagnostic tools aid in determining the absence or presence of specific biomarkers, protein expressions, genetic mutations, etc., linked to the potential side effects and effectiveness of targeted therapies. This, in turn, is propelling the market growth in this segment.

Breakup by Technology:

Immunohistochemistry (IHC)

Polymerase Chain Reaction (PCR)

In-situ Hybridization (ISH)

Real-time PCR (RT-PCR)

Gene Sequencing

Others

Polymerase chain reaction (PCR) exhibits a clear dominance in the market

The report has provided a detailed breakup and analysis of the market based on the technology. This includes immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing, and others. According to the report, polymerase chain reaction (PCR) accounted for the largest market share.

The growth in this segmentation is bolstered by the easy availability of polymerase chain reaction (PCR) kits and reagents used for companion diagnostics. Moreover, their widespread applications in detecting gene mutations with low or limited allele frequencies are contributing to their dominance in the global market.

Breakup by Indication:

Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancer

Melanoma

Others

Neurological Diseases

Infectious Diseases

Cardiovascular Diseases

Others

Cancer currently accounts for the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the indication. This includes cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma, and others), neurological diseases, infectious diseases, cardiovascular diseases, and others. According to the report, cancer represented the largest segment.

The widespread incidence of cancer is propelling the usage of companion diagnostics, thereby fueling the market growth in this segmentation. According to the American Cancer Society, in January 2022, 1.9 million cancer cases were recorded in the U.S. Consequently, continuous product launches and approvals by government bodies are positively influencing the companion diagnostics market growth in this segmentation. For example, in October 2021, the United States Food and Drug Administration approved Agilent's Ki-67 IHC MIB-1 pharmDx (Dako Omnis), which assisted in identifying patients with early breast cancer (EBC). Besides this, according to the Lung Cancer Research Foundation, in the United States estimated 236,740 individuals were diagnosed with lung cancer in 2022, thereby propelling the need for lung cancer companion diagnostics.

Breakup by End User:

Pharmaceutical & Biopharmaceutical Companies

Reference Laboratories

Contract Research Organizations

Others

Pharmaceutical & biopharmaceutical companies hold the largest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical & biopharmaceutical companies, reference laboratories, contract research organizations, and others. According to the report, pharmaceutical & biopharmaceutical companies accounted for the largest market share.

The rising adoption of companion diagnostics by pharmaceutical & biopharmaceutical companies in drug development is one of the primary factors propelling the market growth in this segmentation. Moreover, the inflating popularity of companion diagnostics biomarkers is also acting as another significant growth-inducing factor.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest companion diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America currently dominates the global market, with the United States emerging as a major contributor. Strategic collaborations among biopharmaceutical companies and companion diagnostic manufacturers are primarily augmenting the regional market. For example, QIAGEN and Denovo Biopharma partnered to develop a companion diagnostic test for the treatment of diffuse large B-Cell Lymphoma (DLBCL). Furthermore, the increasing drug approvals by governing authorities, such as the United States Food and Drug Administration (US FDA), are projected to bolster the companion diagnostics market in North America over the forecasted period.

Leading Key Players in the Companion Diagnostics Industry:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies

BioMerieux

Danaher Corporation

Roche Holding AG

Myriad Genetics Inc.

Siemens Healthcare

Thermo Fisher Scientific Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Companion Diagnostics Market News:

March 2024: Thermo Fisher Scientific announced a collaboration with Bayer AG BAYRY to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx).

February 2024: Roche has partnered with PathAI to leverage artificial intelligence (AI) to introduce algorithms for companion diagnostics.

December 2023: A German electronics firm, Siemens, contracted to commercialize and develop companion diagnostics by Pfizer.

Key Questions Answered in This Report

  • 1. What was the size of the global companion diagnostics market in 2023?
  • 2. What is the expected growth rate of the global companion diagnostics market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global companion diagnostics market?
  • 4. What are the key factors driving the global companion diagnostics market?
  • 5. What is the breakup of the global companion diagnostics market based on the product & service?
  • 6. What is the breakup of the global companion diagnostics market based on the technology?
  • 7. What is the breakup of the global companion diagnostics market based on the indication?
  • 8. What is the breakup of the global companion diagnostics market based on the end user?
  • 9. What are the key regions in the global companion diagnostics market?
  • 10. Who are the key players/companies in the global companion diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Companion Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product & Service

  • 6.1 Assays, Kits and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Software and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Immunohistochemistry (IHC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 In-situ Hybridization (ISH)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Real-time PCR (RT-PCR)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Gene Sequencing
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Lung Cancer
      • 8.1.2.2 Breast Cancer
      • 8.1.2.3 Colorectal Cancer
      • 8.1.2.4 Gastric Cancer
      • 8.1.2.5 Melanoma
      • 8.1.2.6 Others
    • 8.1.3 Market Forecast
  • 8.2 Neurological Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiovascular Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical & Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Reference Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Contract Research Organizations
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 BioMerieux
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Roche Holding AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 Myriad Genetics Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Siemens Healthcare
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Thermo Fisher Scientific Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Companion Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Companion Diagnostics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Companion Diagnostics Market: Breakup by Product & Service (in %), 2023
  • Figure 4: Global: Companion Diagnostics Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Companion Diagnostics Market: Breakup by Indication (in %), 2023
  • Figure 6: Global: Companion Diagnostics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Companion Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Companion Diagnostics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Companion Diagnostics (Assays, Kits and Reagents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Companion Diagnostics (Assays, Kits and Reagents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Companion Diagnostics (Software and Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Companion Diagnostics (Software and Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Companion Diagnostics (Immunohistochemistry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Companion Diagnostics (Immunohistochemistry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Companion Diagnostics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Companion Diagnostics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Companion Diagnostics (In-situ Hybridization) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Companion Diagnostics (In-situ Hybridization) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Companion Diagnostics (Real-time PCR) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Companion Diagnostics (Real-time PCR) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Companion Diagnostics (Gene Sequencing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Companion Diagnostics (Gene Sequencing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Companion Diagnostics (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Companion Diagnostics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Companion Diagnostics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Companion Diagnostics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Companion Diagnostics (Neurological Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Companion Diagnostics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Companion Diagnostics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Companion Diagnostics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Companion Diagnostics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Companion Diagnostics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Companion Diagnostics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Companion Diagnostics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Companion Diagnostics (Reference Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Companion Diagnostics (Reference Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Companion Diagnostics (Contract Research Organizations) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Companion Diagnostics (Contract Research Organizations) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Companion Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Companion Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia Pacific: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia Pacific: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Companion Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Companion Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Companion Diagnostics Industry: SWOT Analysis
  • Figure 93: Global: Companion Diagnostics Industry: Value Chain Analysis
  • Figure 94: Global: Companion Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Companion Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Companion Diagnostics Market Forecast: Breakup by Product & Service (in Million US$), 2024-2032
  • Table 3: Global: Companion Diagnostics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Companion Diagnostics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: Companion Diagnostics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Companion Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Companion Diagnostics Market Structure
  • Table 8: Global: Companion Diagnostics Market: Key Players